caa a22 4500 46578464X CHVBK 20180323112004.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00811445 doi (NATIONALLICENCE)springer-10.1007/BF00811445 Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies [Elektronische Daten] [W. Becker, F. Emmrich, G. Horneff, G. Burmester, F. Seiler, A. Schwarz, J. Kalden, F. Wolf] CD4 expressing T-lymphocytes are involved in the pathogenesis of rheumatoid arthritis, so the possibility of using radiolabelled CD4-specific antibodies to localise diseased joints was studied. Prospectively six patients with rheumatoid arthritis were investigated. Five of them received 200-300 μg of a 555 MBq technetium 99m CD4-specific antibody (MAX.16H5) and were examined with three phase bone scans. Max.16H5 (IgG1) was labelled according to the mercaptoethanol (Schwarz) method. Lymphocytes of one patient were isolated on a Ficoll-Hypaque gradient and labelled with the antibody in vitro. Scans were performed 1.5 h, 4 and 24 h post injection in anterior and posterior views. In all patients, diseased joints could be clearly imaged at as early as 1.5 h. The localisation of the diseased joints correlated (P<0.01) with the clinical signs, with the early methylene diphosphonate (MDP) scan (P > 0.01) and only weakly with the late bone scan (P > 0.05). According to these data we conclude that99mTc-labelled CD4-specific antibodies specifically image actively diseased joints in rheumatoid arthritis. Springer-Verlag, 1990 Immunoscintigraphy nationallicence Technetium 99m-labelled antibodies nationallicence CD4-specific (T-lymphocyte) antibodies nationallicence Rheumatoid arthritis nationallicence Localisation nationallicence Becker W. Department of Nuclear Medicine, Germany aut Emmrich F. Max-Planck-Society, Clinical Research Group for Rheumatology/Immunology, Germany aut Horneff G. Institute of Clinical Immunology and Rheumatology, Department of Medicine III, University of Erlangen-Nürnberg, Germany aut Burmester G. Institute of Clinical Immunology and Rheumatology, Department of Medicine III, University of Erlangen-Nürnberg, Germany aut Seiler F. Radiochemical Laboratory of the Behring Werke, Frankfurt, Germany aut Schwarz A. Radiochemical Laboratory of the Behring Werke, Frankfurt, Germany aut Kalden J. Institute of Clinical Immunology and Rheumatology, Department of Medicine III, University of Erlangen-Nürnberg, Germany aut Wolf F. Department of Nuclear Medicine, Germany aut European Journal of Nuclear Medicine Springer-Verlag 17/3-4(1990-03-01), 156-159 0340-6997 17:3-4<156 1990 17 259 https://doi.org/10.1007/BF00811445 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00811445 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Becker W. Department of Nuclear Medicine, Germany aut NATIONALLICENCE 700 1- Emmrich F. Max-Planck-Society, Clinical Research Group for Rheumatology/Immunology, Germany aut NATIONALLICENCE 700 1- Horneff G. Institute of Clinical Immunology and Rheumatology, Department of Medicine III, University of Erlangen-Nürnberg, Germany aut NATIONALLICENCE 700 1- Burmester G. Institute of Clinical Immunology and Rheumatology, Department of Medicine III, University of Erlangen-Nürnberg, Germany aut NATIONALLICENCE 700 1- Seiler F. Radiochemical Laboratory of the Behring Werke, Frankfurt, Germany aut NATIONALLICENCE 700 1- Schwarz A. Radiochemical Laboratory of the Behring Werke, Frankfurt, Germany aut NATIONALLICENCE 700 1- Kalden J. Institute of Clinical Immunology and Rheumatology, Department of Medicine III, University of Erlangen-Nürnberg, Germany aut NATIONALLICENCE 700 1- Wolf F. Department of Nuclear Medicine, Germany aut NATIONALLICENCE 773 0- European Journal of Nuclear Medicine Springer-Verlag 17/3-4(1990-03-01), 156-159 0340-6997 17:3-4<156 1990 17 259 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer